Literature DB >> 22810970

Prognostic significance of volume-based metabolic parameters in uterine cervical cancer determined using 18F-fluorodeoxyglucose positron emission tomography.

Jang Yoo1, Joon Young Choi, Seung Hwan Moon, Duk Soo Bae, Soo Bin Park, Yearn Seong Choe, Kyung-Han Lee, Byung-Tae Kim.   

Abstract

OBJECTIVE: We compared the prognostic value of volume-based metabolic parameters determined using fluorine 18 (F) fluorodeoxyglucose (FDG) positron emission tomography (PET) (F-FDG PET) (with other prognostic parameters in uterine cervical cancer.
METHODS: The subjects were 73 female patients who had an initial diagnosis of uterine cervical cancer and who underwent F-FDG PET. Various metabolic or volume-based PET parameters including maximum and average standardized uptake values, metabolic tumor volume, and total lesion glycolysis (TLG) were measured in primary cervical tumors. Survival analysis for disease-free survival or progression-free survival was performed with a Kaplan-Meier method using PET parameters and other clinical variables. For determining independent prognostic factors, Cox regression analysis was performed.
RESULTS: Recurrence or disease progression occurred in 23 patients (31.5%). In univariate analysis, patient age (cutoff, 57 years, P < 0.05), International Federation of Gynecology and Obstetrics stage (P = 0.07), primary tumor size (cutoff, 6.7 cm; P < 0.05), lymph node status on PET (P < 0.005), treatment method (P < 0.01), metabolic tumor volume (cutoff, 82 cm; P = 0.001), and TLG (cutoff, 7600; P = 0.005) were significant predictors of recurrence or progression. In multivariate analysis, both lymph node status on PET (hazard ratio, 1.042 [negative vs intrapelvic metastasis only], 7.008 [negative vs extrapelvic metastasis]; P < 0.001) and TLG (cutoff, 7600; hazard ratio, 2.981; P < 0.05) were independent prognostic factors for predicting recurrence.
CONCLUSIONS: In uterine cervical cancer, TLG, a volume-based metabolic parameter, and lymph node status on PET may be significant independent prognostic factors for event-free survival.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22810970     DOI: 10.1097/IGC.0b013e318260a905

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  25 in total

1.  The role of metabolic tumor volume and total lesion glycolysis on ¹⁸F-FDG PET/CT in the prognosis of epithelial ovarian cancer.

Authors:  Jeong Won Lee; Arthur Cho; Jae-Hoon Lee; Mijin Yun; Jong Doo Lee; Young Tae Kim; Won Jun Kang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-05-23       Impact factor: 9.236

2.  Comparison of FDG PET metabolic tumour volume versus ADC histogram: prognostic value of tumour treatment response and survival in patients with locally advanced uterine cervical cancer.

Authors:  Yoshiko Ueno; Robert Lisbona; Tsutomu Tamada; Amer Alaref; Kazuro Sugimura; Caroline Reinhold
Journal:  Br J Radiol       Date:  2017-06-16       Impact factor: 3.039

3.  Prognostic value of whole-body metabolic tumour volume and total lesion glycolysis measured on ¹⁸F-FDG PET/CT in patients with extranodal NK/T-cell lymphoma.

Authors:  Choon-Young Kim; Chae Moon Hong; Do-Hoon Kim; Seung Hyun Son; Shin Young Jeong; Sang-Woo Lee; Jaetae Lee; Byeong-Cheol Ahn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-05-15       Impact factor: 9.236

4.  Primary tumor SUVmax on preoperative FDG-PET/CT is a prognostic indicator in stage IA2-IIB cervical cancer patients treated with radical hysterectomy.

Authors:  Shigetaka Yagi; Tamaki Yahata; Yasushi Mabuchi; Yuko Tanizaki; Aya Kobayashi; Michihisa Shiro; Nami Ota; Sawako Minami; Masaki Terada; Kazuhiko Ino
Journal:  Mol Clin Oncol       Date:  2016-07-07

Review 5.  Current Methods to Define Metabolic Tumor Volume in Positron Emission Tomography: Which One is Better?

Authors:  Hyung-Jun Im; Tyler Bradshaw; Meiyappan Solaiyappan; Steve Y Cho
Journal:  Nucl Med Mol Imaging       Date:  2017-09-19

6.  Pretreatment metabolic tumour volume and total lesion glycolysis are not independent prognosticators for locally advanced cervical cancer patients treated with chemoradiotherapy.

Authors:  Ozan Cem Guler; Nese Torun; Berna Akkus Yildirim; Cem Onal
Journal:  Br J Radiol       Date:  2018-01-10       Impact factor: 3.039

7.  Multiparametric PET/MR (PET and MR-IVIM) for the evaluation of early treatment response and prediction of tumor recurrence in patients with locally advanced cervical cancer.

Authors:  Si Gao; Siyao Du; Zaiming Lu; Jun Xin; Song Gao; Hongzan Sun
Journal:  Eur Radiol       Date:  2019-09-06       Impact factor: 5.315

8.  Volume-based quantitative FDG PET/CT metrics and their association with optimal debulking and progression-free survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery.

Authors:  H A Vargas; I A Burger; D A Goldman; M Miccò; R E Sosa; W Weber; D S Chi; H Hricak; E Sala
Journal:  Eur Radiol       Date:  2015-04-28       Impact factor: 5.315

9.  Prognostic Value of Volume-Based Metabolic Parameters Measured by (18)F-FDG PET/CT of Pancreatic Neuroendocrine Tumors.

Authors:  Ho Seong Kim; Joon Young Choi; Dong Wook Choi; Ho Yeong Lim; Joo Hee Lee; Sun Pyo Hong; Young Seok Cho; Kyung-Han Lee; Byung-Tae Kim
Journal:  Nucl Med Mol Imaging       Date:  2014-02-07

10.  A preliminary investigation into textural features of intratumoral metabolic heterogeneity in (18)F-FDG PET for overall survival prognosis in patients with bulky cervical cancer treated with definitive concurrent chemoradiotherapy.

Authors:  Kung-Chu Ho; Yu-Hua Dean Fang; Hsiao-Wen Chung; Tzu-Chen Yen; Tsung-Ying Ho; Hung-Hsueh Chou; Ji-Hong Hong; Yi-Ting Huang; Chun-Chieh Wang; Chyong-Huey Lai
Journal:  Am J Nucl Med Mol Imaging       Date:  2016-07-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.